Evozyne, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Evozyne, Inc. - overview
Established
2020
Location
Chicago, IL, US
Primary Industry
Biotechnology
About
Based in Illinois, US, and founded in 2020 by co-founders Rama Ranganathan, and Andrew Ferguson, Evozyne, Inc. operates as a biotechnology company, that offers protein-based solutions designed to address challenges and drive sustainable solutions across various sectors. In September 2023, Evozyne raised USD 81 million in series A funding co-led by OrbiMed Advisors and Fidelity Management and Research Company, with participation from NVentures. Returning investors Paragon Biosciences LLC and Valor Equity Partners also participated in the round.
As of September 2023, the company is led by its CEO Mike Gamson. Evozyne, Inc. 's core product is the development of novel therapeutics such as IgG Protease, CRISPR, and carbon capture with performance characteristics. These proteins have broad applications in various industries, including therapeutics and sustainability.
By leveraging Evozyne's protein engineering technology, these products offer solutions for advancements in areas such as drug development, sustainable energy, and environmental conservation. The company plans to use the series A funding to advance its generative AI-powered drug discovery platform and product development.
Current Investors
OrbiMed Advisors, Valor Equity Partners, Fidelity Management and Research Company
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.evozyne.com
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.